Aptus Pharma IPO Details
The key details of Aptus Pharma’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹13.02 Cr |
| Price Range | ₹65 - ₹70 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | BSE |
| Minimum Quantity | 4,000 |
| Investment (cut-off price) | ₹2,80,000 |
| Pre IPO Promotor Holding | 100% |
| Post IPO Promotor Holding | 72.89% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Aptus Pharma IPO Timelines
The IPO process for Aptus Pharma includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
23/09/2025
Start Date25/09/2025
End Date29/09/2025
Refund Initiation29/09/2025
Credit of Shares to Demat Ac30/09/2025
Listing DateAptus Pharma IPO Lot Size
The Aptus Pharma IPO has a fixed lot size of 2,000 shares, at an upper price band of ₹70 per share. For retail investors, the minimum and maximum application is 4,000 shares (2 lots) amounting to ₹2,80,000. For Small HNI (S-HNI) investors, the minimum application is 6,000 shares (3 lots) worth ₹4,20,000, while the maximum is 14,000 shares (7 lots) amounting to ₹9,80,000. Big HNI (B-HNI) investors need to apply for at least 16,000 shares (8 lots), totaling ₹11,20,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 4000 | ₹2,80,000 |
| Retail Maximum | 2 | 4000 | ₹2,80,000 |
| S-HNI Minimum | 3 | 6000 | ₹4,20,000 |
| S-HNI Maximum | 7 | 14000 | ₹9,80,000 |
| B-HNI Minimum | 8 | 16000 | ₹11,20,000 |
Aptus Pharma IPO Subscription Status
The subscription status for Aptus Pharma IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.24x | 28.75x | 31.43x | -- | 22.27x |
IPO Performance on Listing Day
On the listing day (September 30, 2025), Aptus Pharma made a strong debut on the stock exchange. The stock opened at ₹80.80, securing an impressive premium of 15.4% over its issue price of ₹70. The pharmaceutical company gained further momentum throughout the trading session, reaching a day high of ₹84.84, while finding solid support at the opening price level. The shares concluded their first trading day at ₹84.84, which also marked the day’s high, delivering an exceptional gain of 21.2% over the issue price, reflecting robust investor confidence in the pharmaceutical sector and strong market appetite for healthcare and drug manufacturing companies.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹80.80 | ₹84.84 | ₹84.84 | ₹80.80 |
Aptus Pharma IPO Company Financials
Aptus Pharma reports robust performance in FY2025 with Total Income of ₹24.64 crores, managing expenses at ₹20.44 crores, and achieving a strong PAT (Profit After Tax) of ₹3.10 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹13.90 | ₹13.60 | ₹0.19 |
| FY 2024 | ₹17.88 | ₹16.76 | ₹0.80 |
| FY 2025 | ₹24.64 | ₹20.44 | ₹3.10 |
About Company
Incorporated in 2010, Aptus Pharma Ltd is involved in the marketing and distribution of finished pharmaceutical formulations. The company offers a wide range of products across multiple therapeutic areas including antacids and proton pump inhibitors, pain management, anti-inflammatories, antibiotics, cardiology and antidiabetics, neuropsychiatry, dental care, injectable parenterals, syrups, nutraceuticals, sachets, and more. Its product portfolio is organized under different divisions such as Aptus Pharma for acute therapies, Aptus CD Care for chronic therapies, Aptus Wellcare for wellness and nutraceutical products, and Aptus Global for exports to overseas markets.
As of March 31, 2025, the company had a total of 194 pharmaceutical formulations spread across more than eleven therapeutic segments. Its warehousing operations are based in Ahmedabad, Gujarat, with facilities covering a combined area of 17,721 square feet. Aptus Pharma operates through a distribution network of 125 direct and sub-distributors and is supported by a sales team of 54 field personnel. The company employed 70 staff members as of March 2025, reflecting its focused yet expanding presence in the pharmaceutical sector.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2010 | Pharmaceuticals | Tejash hathi |
Know Before Investing
Aptus Pharma IPO Strengths
- The company’s revenue has grown steadily from ₹13.90 crore in FY23 to ₹24.64 crore in FY25, reflecting strong business expansion.
- Profit after tax (PAT) surged from ₹0.19 crore in FY23 to ₹3.10 crore in FY25, showing enhanced operational efficiency and margin improvement.
- Net asset value per share and net worth have shown steady improvement, enhancing shareholder value.
- Aptus Pharma operates in the pharmaceutical sector with specialized products benefiting from growing healthcare demand.
- The company reports a high return on equity (ROE) of 44.50% and return on capital employed (ROCE) of 45.66%, which suggests efficient capital utilization.
Aptus Pharma IPO Risks
- Aptus Pharma is a relatively small company with limited operating history, which may pose risks related to scalability and sustainability of financial performance.
- The company’s margins and profits could be impacted by fluctuating costs of raw materials and operational expenses, affecting overall profitability.
- Being in the pharmaceutical sector, the company faces risks related to regulatory approvals, changes in drug pricing policies, and compliance with quality standards.
- Aptus Pharma’s reliance on contract manufacturers can expose the company to risks related to production delays, quality issues, and cost escalations.
- Business operations require significant working capital due to inventory and receivables, which may strain liquidity and increase financial costs.
- The pharmaceutical sector is highly competitive with numerous domestic and international players; this can result in pricing pressures and loss of market share.
- Fluctuating macroeconomic conditions, changes in healthcare spending, and economic downturns may adversely affect demand for the company’s products.
Swot Analysis for Aptus Pharma IPO
Strengths
Growing Financials, Robust Regulatory Compliance, Solid Local Market Presence
Weaknesses
Limited Scale of Operations, Geographical Concentration, Modest Research & Development
Opportunities
Expanding Therapeutic Portfolio, Growing Healthcare Spending, Digital Marketing & Telemedicine
Threats
Intense Industry Competition, Counterfeit and Quality Issues, Raw Material Price Fluctuations
Company Details
Aptus Pharma Ltd.
Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/
IPO Registar Details
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
FAQs
The key objectives of Aptus Pharma SME IPO are:
- Capital Expenditure for Office Premises with furniture and Industrial Racks
- Working Capital
- General corporate purposes
Interactive Financial Services Ltd. is the book-running lead managers for the Aptus Pharma IPO.
Aptus Pharma IPO shows meaningful growth potential with revenue rising from ₹13.90 crore in FY23 to ₹24.64 crore in FY25 and profit after tax improving to ₹3.10 crore. Expanding operations and an asset light model support scalability though high leverage and working capital stress remain key challenges.
The issue price for the Aptus Pharma IPO is set between ₹65 to ₹70 per share.
To invest in two lot of Aptus Pharma IPO, you need ₹2,60,000 at the lower price band (₹65 per share) or ₹2,80,000 at the upper price band (₹70 per share) for a lot size of 4000 shares.
Aptus Pharma IPO shares are scheduled to be listed on the Bombay Stock Exchange (BSE) on September 30, 2025.
Refund/unblocking of funds for Aptus Pharma IPO will begin on September 29, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Aptus Pharma IPO shares on listing day (September 30, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.